Ganciclovir
* Please be kindly noted products are not for therapeutic use. We do not sell to patients.
| Category | Antiviral |
| Catalog number | BBF-04047 |
| CAS | 82410-32-0 |
| Molecular Weight | 255.23 |
| Molecular Formula | C9H13N5O4 |
| Purity | >98% |
Online Inquiry
Description
Ganciclovir is an antiviral drug for feline herpesvirus type-1 with IC50 of 5.2 μM.
Specification
| Related CAS | 107910-75-8 (sodium) |
| Synonyms | Cytovene; BW 759; BW759; BW-759; 2'-Nor-2'-deoxyguanosine |
| Storage | Store at -20°C |
| IUPAC Name | 2-amino-9-(1,3-dihydroxypropan-2-yloxymethyl)-1H-purin-6-one |
| Canonical SMILES | C1=NC2=C(N1COC(CO)CO)NC(=NC2=O)N |
| InChI | InChI=1S/C9H13N5O4/c10-9-12-7-6(8(17)13-9)11-3-14(7)4-18-5(1-15)2-16/h3,5,15-16H,1-2,4H2,(H3,10,12,13,17) |
| InChI Key | IRSCQMHQWWYFCW-UHFFFAOYSA-N |
Properties
| Appearance | White Solid |
| Application | Antiviral agents |
| Antibiotic Activity Spectrum | viruses |
| Boiling Point | 675°C at 760 mmHg |
| Melting Point | 251-252°C |
| Density | 1.81 g/cm3 |
| Solubility | Soluble in DMSO |
Reference Reading
1.Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected in Vitro that Confer Brincidofovir Resistance.
Chou S1, Ercolani RJ2, Lanier ER3. Antimicrob Agents Chemother. 2016 Apr 4. pii: AAC.00214-16. [Epub ahead of print]
Eight in vitro selection experiments under brincidofovir elicited known cytomegalovirus DNA polymerase amino acid substitutions N408K and V812L, and novel exonuclease domain substitutions D413Y, E303D and E303G, which conferred ganciclovir and cidofovir resistance with 6- to 11-fold resistance to brincidofovir, or 17-fold when E303G was combined with V812L. The new exonuclease domain I resistance mutations selected under brincidofovir pressure add to the single instance previously reported and show the expected patterns of cross resistance.
2.A case of Chagas' disease panniculitis after kidney transplantation.
Campos FP1, Pansard HM1, Arantes LC1, Rodrigues AT1, Daubermann MF1, Azambuja MF1, Argenta LC1, Silva LA1. J Bras Nefrol. 2016 Mar;38(1):127-131.
Chagas' disease carries high morbidity and mortality due to acute parasitemia or cardiac, digestive, cutaneous or neurologic chronic lesions. Latin American countries have the majority of infected or at risk people. Transplanted patients using immunosuppressive agents may develop severe and even fatal forms of the disease. The available treatment causes frequent severe side-effects. A 59 years-old woman with end stage renal disease and positive serology for Chagas` disease, but without any clinical manifestation of this pathology, underwent kidney transplantation from a cadaveric donor and displayed three months later a thigh panniculitis from which a biopsy unveiled amastigote forms of Trypanosoma cruzi. The skin lesions disappeared following treatment with benzonidazole, but the drug was discontinued due to severe pancytopenia. Along with this, infection with E. faecalis and cytomegalovirus were treated with vancomicin and ganciclovir.
3.Encephalitis caused by an unusual HHV-6 - Toxoplasma gondii coinfection in a cord blood transplant recipient.
Chapuis A1, Chabrot C2, Mirand A3, Poirier P4, Nourrisson C5. Int J Infect Dis. 2016 Apr 6. pii: S1201-9712(16)31015-3. doi: 10.1016/j.ijid.2016.04.002. [Epub ahead of print]
BACKGROUND: We report the first case of central nervous system coinfection by human herpes virus-6 (HHV-6) and Toxoplasma gondii, after umbilical cord blood transplantation, in a chronic leukemia myelomonocytic patient.
4.Preclinical Efficacy and Safety Profile of Allometrically Scaled Doses of Doxycycline Used to Turn "On" Therapeutic Transgene Expression from High-Capacity Adenoviral Vectors in a Glioma Model.
VanderVeen NT1, Raja NS2,3, Yi E4,5, Appelman H6, Ng P7, Palmer D8, Zamler D9,10, Dzaman M9,11, Lowenstein P9,12, Castro M13,14. Hum Gene Ther Methods. 2016 Apr 8. [Epub ahead of print]
Glioblastoma multiforme (GBM) is the most commonly occurring primary brain cancer in adults, where its highly infiltrative cells prevent total surgical resection, often leading to tumor recurrence and patient death. Our group has discovered a gene therapy approach for GBM that utilizes high-capacity "gutless" adenoviral vectors encoding regulatable therapeutic transgenes. The herpes simplex type 1-thymidine kinase (TK) actively kills dividing tumor cells in the brain when in the presence of the prodrug, Ganciclovir (GCV), while the FMS-like tyrosine kinase 3 ligand (Flt3L) is an immune-stimulatory molecule under tight regulation by a tetracycline-inducible "Tet-On" activation system that induces anti-GBM immunity. As a prelude to a Phase I clinical trial, we evaluated the safety and efficacy of Food and Drug Administration (FDA)-approved doses of the tetracycline Doxycycline (DOX) allometrically scaled for rats. DOX initiates the expression of Flt3L, which has been shown to recruit dendritic cells (DCs) to the brain tumor microenvironment; an integral first step in the development of anti-tumor immunity.
Recommended Products
| BBF-01826 | Deoxymannojirimycin | Inquiry |
| BBF-01829 | Deoxynojirimycin | Inquiry |
| BBF-01825 | Loganin | Inquiry |
| BBF-01693 | Doxorubicin EP Impurity A (Daunorubicin) | Inquiry |
| BBF-03754 | CASTANOSPERMINE | Inquiry |
| BBF-02614 | Nystatin | Inquiry |
Bio Calculators
* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2
* Total Molecular Weight:
g/mol
Tip: Chemical formula is case sensitive. C22H30N4O √ c22h30n40 ╳
